Jones Financial Companies Lllp Purchases Shares of 2,169 Stryker Corporation $SYK

Jones Financial Companies Lllp acquired a new stake in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 2,169 shares of the medical technology company’s stock, valued at approximately $683,000.

A number of other large investors have also recently made changes to their positions in the company. Sankala Group LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at approximately $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $27,000. Finally, Gables Capital Management Inc. acquired a new stake in shares of Stryker in the 2nd quarter valued at $25,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 355,370 shares of company stock worth $119,447,201. 4.60% of the stock is owned by company insiders.

Stryker Trading Down 0.5%

SYK opened at $327.80 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The business’s 50 day moving average is $327.39 and its two-hundred day moving average is $332.16. The firm has a market cap of $125.73 billion, a price-to-earnings ratio of 33.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SYK. Needham & Company LLC decreased their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.